Significant variables predictive of outcome on multivariable analysis
. | OR/HR . | 95% CI . | P . |
---|---|---|---|
Complete remission | |||
WBC | 0.90* | 0.85-0.96 | .001 |
Sex, male | 0.58 | 0.41-0.81 | .002 |
Age | .043 | ||
70-79 y | 0.93† | 0.65-1.34 | |
80 y or older | 0.32† | 0.13-0.82 | |
Cytogenetics | <.001 | ||
Rare aberrations | 1.41‡ | 0.56-3.54 | |
1 or 2 nonrare aberrations | 4.80‡ | 2.91-7.92 | |
Disease-free survival | |||
WBC | 1.06* | 1.02-1.11 | .013 |
Sex, male | 1.29 | 1.01-1.64 | .040 |
Age | .014 | ||
70-79 y | 1.17† | 0.91-1.50 | |
80 y or older | 3.60† | 1.66-7.78 | |
Cytogenetics | <.001 | ||
Complex ≥5 | 3.46§ | 2.07-5.78 | |
Overall survival | |||
WBC | 1.05* | 1.02-1.08 | .002 |
Sex, male | 1.39 | 1.18-1.65 | .001 |
% marrow blasts | 1.06∥ | 1.01-1.11 | .012 |
Age | .001 | ||
70-79 y | 1.23† | 1.04-1.47 | |
80 y or older | 2.04† | 1.37-3.06 | |
Cytogenetics | <.001 | ||
Complex ≥5 | 4.49¶ | 2.85-7.06 | |
Rare aberrations | 2.23¶ | 1.31-3.79 | |
Fewer than 5 non-CBF AML, nonrare aberrations | 1.52¶ | 1.03-2.25 |
. | OR/HR . | 95% CI . | P . |
---|---|---|---|
Complete remission | |||
WBC | 0.90* | 0.85-0.96 | .001 |
Sex, male | 0.58 | 0.41-0.81 | .002 |
Age | .043 | ||
70-79 y | 0.93† | 0.65-1.34 | |
80 y or older | 0.32† | 0.13-0.82 | |
Cytogenetics | <.001 | ||
Rare aberrations | 1.41‡ | 0.56-3.54 | |
1 or 2 nonrare aberrations | 4.80‡ | 2.91-7.92 | |
Disease-free survival | |||
WBC | 1.06* | 1.02-1.11 | .013 |
Sex, male | 1.29 | 1.01-1.64 | .040 |
Age | .014 | ||
70-79 y | 1.17† | 0.91-1.50 | |
80 y or older | 3.60† | 1.66-7.78 | |
Cytogenetics | <.001 | ||
Complex ≥5 | 3.46§ | 2.07-5.78 | |
Overall survival | |||
WBC | 1.05* | 1.02-1.08 | .002 |
Sex, male | 1.39 | 1.18-1.65 | .001 |
% marrow blasts | 1.06∥ | 1.01-1.11 | .012 |
Age | .001 | ||
70-79 y | 1.23† | 1.04-1.47 | |
80 y or older | 2.04† | 1.37-3.06 | |
Cytogenetics | <.001 | ||
Complex ≥5 | 4.49¶ | 2.85-7.06 | |
Rare aberrations | 2.23¶ | 1.31-3.79 | |
Fewer than 5 non-CBF AML, nonrare aberrations | 1.52¶ | 1.03-2.25 |
OR indicates odds ratio for complete remission; HR, hazard ratio of relapse and/or death for DFS and OS; and WBC, white blood cell count.
OR/HR for a change in WBC of 20 × 109/L.
OR/HR are relative to age 60 to 69 years.
OR relative to complex karyotype ≥ 3.
HR relative to all other karyotypes.
HR for an increase in bone marrow blasts of 10%.
HR relative to CBF AML group.